Volume 12.25 | Jun 30

MESCN Volume 12.25 | Jun 30
Mesenchymal Cell News by STEMCELL Technologies
Vol. 12.25 – 30 June, 2020

New Insights into Molecular and Cellular Mechanisms of Zoledronate in Human Osteosarcoma

The authors provide the available literature on in vitro studies to illustrate the new insights into the intracellular molecular mechanisms of zoledronate in human osteosarcoma cell lines.
[Pharmacology & Therapeutics]


Virtual Conference Exhibition: Pluripotent Stem Cells
PUBLICATIONSRanked by the impact factor of the journal

LncRNA ENST00000563492 Promoting the Osteogenesis-Angiogenesis Coupling Process in Bone Mesenchymal Stem Cells (BMSCs) by Functions as a ceRNA for miR-205-5p

Investigators found that lncRNA ENST00000563492 was downregulated in bone nonunion tissues. LncRNA ENST00000563492 promoted osteogenic differentiation of BMSCs through upregulating the expression of CDH11.
[Cell Death & Disease]

Full Article

Peripheral Blood As a Source of Stem Cells for Regenerative Medicine: Emphasis towards Corneal Epithelial Reconstruction – An In Vitro Study

Rabbit peripheral blood-derived mononuclear cells were isolated using density gradient centrifugation and was evaluated for mesenchymal cell properties including stemness.
[Journal of Tissue Engineering and Regenerative Medicine]


Effect of Donor Age and 3D-Cultivation on Osteogenic Differentiation Capacity of Adipose-Derived Mesenchymal Stem Cells

Alkaline phosphatase (ALP) activity revealed highest levels in 3D of old adipose-derived MSCs after 14 days. ALP expression showed significant rises in old versus young cells in 2D.
[Scientific Reports]

Full Article

RNA-Sequencing Reveals Positional Memory of Multipotent Mesenchymal Stromal Cells from Oral and Maxillofacial Tissue Transcriptomes

Scientists isolated and characterized human MSCs from three different bones, maxilla and mandible and proceeded with next generation RNA-sequencing.
[BMC Genomics]

Full Article

miR-200b in Heme Oxygenase-1-Modified Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Alleviates Inflammatory Injury of Intestinal Epithelial Cells by Targeting High Mobility Group Box 3

Researchers identified that exosomes derived from HO-1/BMMSCs played an important role in alleviating the inflammatory injury of intestinal epithelial cells (IECs). The mechanism was related to miR-200b targeting the abnormally increased expression of the high mobility group box 3 (HMGB) gene in IECs induced by inflammatory injury. The reduced level of HMGB3 then decreased the inflammatory injury.
[Cell Death & Disease]

Full Article

Cutaneous Wound Healing: Canine Allogeneic ASC Therapy

The percentage of the wounds that exhibited contraction and re-epithelialization were significantly different between wounds treated with adipose mesenchymal stem cells and control wounds.
[Stem Cell Research & Therapy]

Full Article

G-CSF Inhibits Pulmonary Fibrosis by Promoting BMSC Homing to the Lungs via SDF-1/CXCR4 Chemotaxis

Investigators found that bone marrow mesenchymal stem cells could inhibit fibroblast proliferation and transdifferentiation into myofibroblasts through paracrine actions.
[Scientific Reports]

Full Article

Effect of Aging and 5-Fluorouracil Treatment on Bone Marrow Stem Cell Dynamics

CD44 positive aged MSCs showed increased proliferation on D10. Transplanting MSCs from young mice in 5-Fluorouracil treated aged marrow helped improve hematopoiesis.
[Stem Cell Reviews and Reports]


miR-132-3p Priming Enhances the Effects of Mesenchymal Stromal Cell-Derived Exosomes on Ameliorating Brain Ischemic Injury

Mesenchymal stromal cell-derived exosomes could deliver their carried miR-132-3p into target ECs, which functionally downregulated the target protein RASA1, while upregulated the expression of Ras and the downstream PI3K phosphorylation.
[Stem Cell Research & Therapy]

Full Article


Facts and Hopes in Immunotherapy of Soft Tissue Sarcomas

The authors focus on the role of the immune microenvironment in the development and activity of new therapeutic approaches, and the recent identification of the sarcoma immune class (SIC) groups, especially group SIC E with its B cell signature that predicts immunotherapy response.
[Clinical Cancer Research]



Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19

Citius Pharmaceuticals, Inc. announced that the Company has received a written response from the FDA in regards to its pre-investigational new drug application for its induced mesenchymal stem cells to treat and reduce the severity of acute respiratory distress syndrome in patients with COVID-19.
[Citius Pharmaceuticals, Inc. (PR Newswire Association LLC.)]

Press Release

NIH’s New Sexual-Harassment Rules Are Still Too Weak, Say Critics

On 24 June, the US National Institutes of Health (NIH) described the actions it will take when alerted to reports of unsafe behavior, including restricting scientists from peer-review panels, holding back pending grants and refusing university requests to transfer funding to other institutions in cases where a harasser changes jobs.
[Nature News]



Life Science Innovation Northwest Conference

July 16 – July 17

> See All Events


Scientific Project Manager – Tissue Engineering and Regenerative Medicine

Helmholtz Zentrum München – Neuherberg, Germany

Senior Scientist – Process Development Lab, Gene and Cell Therapy

Genezen Laboratories – Indianapolis, Indiana, United States

Postdoctoral Fellow – Mesenchymal Neoplasms

Memorial Sloan Kettering Cancer Center – New York, New York, United States

Postdoctoral Position – Bone Development

KU Leuven – Leuven, Belgium

Postdoctoral Position – Regeneration of Diseased Bone

Radboud umc – Nijmegen, Netherlands

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Mesenchymal Cell News Twitter